TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05511766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 MG
Description: a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: not containing drugs
Study: NCT05956613

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial pulpotomy
Description: Use of newly introduced bioceramic putty in partial pulpotomy
Study: NCT05669170

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychosocial intervention
Description: The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial intervention
Description: The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: norepinephrine and dopamine reuptake inhibitor
Study: NCT05377567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + FIBRO-On
Description: Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + FIBRO-Out
Description: Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study: NCT06331000

Intervention type: DRUG
Intervention: elexacaftor-tezacaftor-ivacaftor treatment
Description: Effect of one year elexacaftor-tezacaftor-ivacaftor treatment on glucose tolerance abnormalities in adult patients with cystic fibrosis
Study: NCT05101993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriClip
Description: Received AtriClip for exclusion of left atrial appendage during concomitant cardiac procedure
Study: NCT06097793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSD-101
Description: Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
Study: NCT05315622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
Description: Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manual tension without reaching the manipulation thrust
Study: NCT05419245

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance Distress
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance Distress
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face.
Study: NCT05970419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high power laser acupuncture (HPLA)
Description: High power laser therapy A Zimmer Opton pro, integrated High-power class IV laser device (serial N: 15200013306 \& REF: 4682, made in Germany, manufactured by Zimmer Medizin System). It emits radiation in the infrared range to deliver topical heating and raise tissue temperature. The simultaneous application of two wavelengths of laser light (810 and 980nm) provides the user with a huge variety of therapy options. The laser probe - with the small spacer (3.1cm2) , with parameters of 3 watts, 5Hz, 50% duty cycle, 20 joule/ point for 13 seconds with 6.4 j/cm2 . Although a maximum power of 8000 W was reported in two studies, the average power of the lasers used in t

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used.
Study: NCT05419245

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance Distress
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance Distress
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance Distress
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Facial Function
Description: Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Facial Function
Description: Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Facial Function
Description: Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Facial Function
Description: Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Facial Function
Description: Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning.
Study: NCT06529432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride Injection
Description: Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
Study: NCT05242445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
Study: NCT05970419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham laser
Description: sham laser (Not active)
Study: NCT05101369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB086550
Description: INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
Study: NCT04798235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TSHA-101
Description: AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
Study: NCT05154058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Subperiosteal Release with Sharp Dissection
Description: Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Subperiosteal Release with Electrocautery
Description: Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
Study: NCT06527885

Intervention type: DRUG
Intervention: Lurasidone
Description: Patients treated with Lurasidone in according to routine clinical practice, in Italy
Study: NCT06446128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20/BCMA CAR T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CD19/CD20/BCMA CAR T cells.~Cyclophosphamide and fludarabine will be given from day-5 to day-3 before the infusion for lymphodepletion. On day0 subjects will receive one dose treatment with CD19/CD20/BCMA CAR T cells by intravenous (IV) injection
Study: NCT06356155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: 1.25 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV
Study: NCT06469983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ErigoBasic or ErigoPro®
Description: Static bed with integrated robotic stepper (ErigoBasic) and optionally integrated with Functional Electrical Stimulation (FES ErigoPro®). The Erigo is a robot designed to be used for early functional mobilisation of patients with neurological manifestations or who are bedridden, even in intensive care. It is a tilt table equipped with an integrated passive stepper controlled by microprocessors that generate physiological leg movements: the patient's thighs are secured by straps to the movement mechanisms and the feet are secured to plates equipped with shock absorbers, while the upper body is held in place by a sling integrated into the table. Erigo provides active functions: gradual elevation in orthostatism up to 90°, controlled and independent mobilisation of the lower limbs, and functional stimulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Verticalization
Description: gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
Study: NCT04322461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaquik MCT supplement
Description: 50g/day divided in 3. Breakfast, lunch and dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaquik MCT supplement
Description: 50g/day divided in 3. Breakfast, lunch and dinner
Study: NCT05857397

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study: NCT06078826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive music therapy
Description: 30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
Study: NCT05242445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC injection or as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC injection or as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC injection or as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC injection or as an IV infusion.
Study: NCT04979949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Turkovac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
Study: NCT04981574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage and stretching on neck area and thoracic thrust manipulation
Description: 1. Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times.
Study: NCT05531708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-mesothelin CAR-T cells
Description: D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
Study: NCT05236400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)
Description: Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual phlegm suction system
Description: Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
Study: NCT04723394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
Study: NCT05906940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
Study: NCT06194006

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up
Description: Follow-up grafted patients as long as their condition allows
Study: NCT05613751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Three text messages that are sent four weeks apart reminding to obtain the vaccines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Three text messages that are sent four weeks apart reminding to obtain the vaccines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Three text messages that are sent four weeks apart reminding to obtain the vaccines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Three text messages that are sent four weeks apart reminding to obtain the vaccines
Study: NCT05606588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playful sensorimotor training
Description: For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue.
Study: NCT04981574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage and stretching on low back area and thoracic thrust manipulation
Description: 1. Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times.